Crossmark

Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG)

Crossref DOI link: https://doi.org/10.1186/s13063-021-05617-7

Published Online: 2021-10-30

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Jinwen

Zhu, Xiu

Du, Yian

Zhu, Yuan

Yu, Pengfei

Yang, Litao

Xu, Zhiyuan

Huang, Ling

Zhang, Yunli

Zhang, Yanqiang

Liu, Luying

Cheng, Xiangdong http://orcid.org/0000-0003-1470-2831
License Information

Text and Data Mining valid from 2021-10-30

Version of Record valid from 2021-10-30
More Information

Article History

Received: 19 October 2020

Accepted: 13 September 2021

First Online: 30 October 2021

Declarations

:

: The protocol has been reviewed and approved by to the medical ethics committee of Cancer Hospital of the University of Chinese Academy of Sciences (IRB-2019-196), and the study has also been registered in ExternalRef removed (NCT03973008, registered on June 1, 2019).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below